The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: The heart 'OMics' in AGEing (HOMAGE) randomized clinical trial

1. Cleland, J.G.F.
2. Ferreira, J.P.
3. Mariottoni, B.
4. Pellicori, P.
5. Cuthbert, J.
6. Verdonschot, J.A.J.
7. Petutschnigg, J.
8. Ahmed, F.Z.
9. Cosmi, F.
10. Brunner La Rocca, H.-P.
11. Mamas, M.A.
12. Clark, A.L.
13. Edelmann, F.
14. Pieske, B.
15. Khan, J.
16. McDonald, K.
17. Rouet, P.
18. Staessen, J.A.
19. Mujaj, B.
20. González, A.
21. Diez, J.
22. Hazebroek, M.
23. Heymans, S.
24. Latini, R.
25. Grojean, S.
26. Pizard, A.
27. Girerd, N.
28. Rossignol, P.
29. Collier, T.J.
30. Zannad, F.
31. Show all authors +

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1093/EURHEARTJ/EHAA758 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus